Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

NCT00809133 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: BIBW 2992
DRUG: Paclitaxel
DRUG: BIBW2992
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Bevacizumab
DRUG: BIBW 2992
DRUG: BIBW 2992

Sponsor

Boehringer Ingelheim